Guardant Health, Inc. income statement & cash flow
In the fiscal year ended Dec 31, 2025, Guardant Health, Inc. reported net income of −$416.28M on revenue of $982.02M. Operating cash flow was −$184.76M and capital expenditures were $48.31M, leaving −$233.07M of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.25M | $49.84M | $90.64M | $214.38M | $286.73M | $373.65M | $449.54M | $563.95M | $739.02M | $982.02M |
| Operating income | −$43.85M | −$76.61M | −$92.94M | −$82.37M | −$254.95M | −$411.00M | −$544.38M | −$564.73M | −$443.59M | −$437.25M |
| Net income | −$46.14M | −$83.22M | −$85.06M | −$75.65M | −$246.28M | −$384.77M | −$654.59M | −$479.45M | −$436.37M | −$416.28M |
| Diluted EPS | — | — | — | −$0.84 | −$2.60 | −$4.00 | −$6.41 | −$4.28 | −$3.56 | −$3.32 |
| Operating cash flow | −$36.71M | −$72.23M | −$72.19M | −$47.13M | −$103.93M | −$209.02M | −$309.46M | −$324.98M | −$239.86M | −$184.76M |
| Capital expenditures | $1.77M | $6.68M | $20.20M | $18.72M | $36.17M | $75.03M | $77.46M | $20.49M | $35.09M | $48.31M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2020 | 10-K 2020 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | -44.5% | -42.4% |
| Dec 2024 | — | -60.0% | -59.0% |
| Dec 2023 | — | -100.1% | -85.0% |
| Dec 2022 | — | -121.1% | -145.6% |
| Dec 2021 | — | -110.0% | -103.0% |
Source: SEC EDGAR XBRL company facts for CIK 1576280 (raw data). Most recent filing in this dataset: 10-Q filed Jul 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.